The pre-seed is a milestones round, not an ideas round. The artefact chain is built. The first deployment is live. This capital closes the gap between “demonstrated in a real deployment” and “deployed commercially at repeatable-pack quality.” Those are the metrics the seed round will be priced on.
40% of the raise goes directly to engineering and product. This is a build-first round. The commercial overhead is minimal because the founders carry the GTM motion personally through Phase 1. No sales hires until the playbook is proven at Seed.
| Stakeholder | Shares / type | % FD | Visualised |
|---|---|---|---|
| Co-Founder 1 (CEO) | Ordinary | 42.5% | |
| Co-Founder 2 (CTO) | Ordinary | 42.5% | |
| Pre-seed investors | Convertible (preferred on conversion) | 15% | |
| Option pool (reserved) | CSOP / EMI unissued | 10% | |
| Total (post pre-seed) | — | 100% | — |
Founding team retains 85% at pre-seed conversion. The cap table is clean: no complex preference stacks, no prior angels, no advisors on equity (cash or carry only at seed). This gives the seed investor a clean entry and preserves founder control through the product-building phase.
Three rounds get Celium to $191.8M ARR by 2035 — total dilution of ~40% from pre-seed through Series A. Each round is triggered by the milestone it funds, not by calendar. The step-up in valuation at each stage reflects the reduction in product, commercial, and operational risk.
| Exit year | Assumed ARR | Exit multiple (ARR) | Implied valuation | Pre-seed MOIC | IRR |
|---|---|---|---|---|---|
| 2032 (early) | $37.9M | 12× | $455M | ~24× | ~54% |
| 2035 (base) | $191.8M | 15× | $2.9bn | ~58× | ~55% |
| 2037 (model) | $402.7M | 12× | $4.8bn | ~92× | 64.9% |
| 2040 (full) | $843M | 10× | $8.4bn | ~130× | ~58% |
The IRR holds across a wide range of exit multiples because the ARR growth is the dominant driver. Even at a conservative 10× ARR exit in 2040, the pre-seed MOIC exceeds 100×. The downside scenario — an early exit at 12× ARR in 2032 — still returns 24× in under 7 years.